Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingkui Yuyang Decoction (QKY) is a traditional Chinese medicinal formula clinically utilized for the treatment of ulcerative colitis (UC). It is a multi-component herbal preparation that has been shown to alleviate intestinal inflammation and mucosal injury. Research using serum pharmacochemistry and network pharmacology has identified several blood-absorbed active components, including loureirin A, berberine, and ellagic acid. The therapeutic mechanism of QKY involves the modulation of the MAPK and NF-κB signaling pathways. Specifically, it downregulates the expression of pro-inflammatory cytokines such as tumor necrosis factor (TNF-α) and interleukin-6 (IL-6), and reduces the phosphorylation of core targets including RELA (p65), AKT1, and p38 MAPK.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingkui Yuyang Decoction.